Titan Pharmaceuticals (TTNP.OB +16.4%) rallies on huge volume.
The FDA has granted the company a Type C meeting for November 19 to discuss exactly what went wrong with the Probuphine NDA.
The company hopes the meeting will provide some "clarity regarding the regulatory path forward" for the buprenorphine implant. (PR)
The stock collapsed in May when the company received the CRL.